NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).
about
The Application of Natural Killer Cell Immunotherapy for the Treatment of CancerEffector Functions of Natural Killer Cell Subsets in the Control of Hematological MalignanciesNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyCell biological steps and checkpoints in accessing NK cell cytotoxicity"Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer ImmunotherapyNK cells in therapy of cancerThe natural killer cell response to West Nile virus in young and old individuals with or without a prior history of infectionCD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling.Impact of Mixed Xenogeneic Porcine Hematopoietic Chimerism on Human NK Cell Recognition in a Humanized Mouse ModelIncreased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against RhabdomyosarcomaHuman CD56dimCD16dim Cells As an Individualized Natural Killer Cell Subset.Human CD6 Down-Modulation following T-Cell Activation Compromises Lymphocyte Survival and Proliferative Responses.Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.Notch signaling at later stages of NK cell development enhances KIR expression and functional maturationTargeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells.Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.NK Cells of Kidney Transplant Recipients Display an Activated Phenotype that Is Influenced by Immunosuppression and Pathological Staging.Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patientsSheddomeDB: the ectodomain shedding database for membrane-bound shed markers.Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damageCombination immune therapies to enhance anti-tumor responses by NK cells.Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).Expansion of CD16 positive and negative human NK cells in response to tumor stimulation.Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.Clinical utility of natural killer cells in cancer therapy and transplantation.Clinical implications of compounds designed to inhibit ECM-modifying metalloproteinases.Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.Natural killer cell receptors: alterations and therapeutic targeting in malignancies.Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.To serve and to protect: the role of decidual innate immune cells on human pregnancy.Predicting NK cell subsets using gene expression levels in peripheral blood and endometrial biopsy specimens.Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes.Mass Cytometry Analytical Approaches Reveal Cytokine-Induced Changes in Natural Killer Cells.Cytokine secretion and NK cell activity in human ADAM17 deficiency.Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
P2860
Q26774678-0782D974-96A4-4944-99CA-FF394BF4006EQ26776538-805E59A7-E2D0-4749-8F81-03A115D869FFQ26797345-ABA79E39-0508-4573-BBF1-3BCFDBA8D0BCQ26852411-1F533FE2-51D3-4ED3-991A-A4160EA08320Q28081338-809FAE7B-270A-45C8-9256-189BEB8AD9C8Q28242241-53090B1B-BECB-4933-9CBB-F22B0BBB4C7CQ29365826-7A5A479A-36D0-4545-84A1-E55CFA093C6CQ33585293-C8CB8263-7825-45D2-8F23-D19A2FAC5966Q33591312-2BE71F69-828A-43DE-BE08-7CCE014594DCQ33629253-91BA2959-985A-4144-8C6B-B7F108F74F8FQ33646189-8B080891-BCD4-45C3-B412-0DFDDDD4479FQ33785788-7CF362B3-C271-4A2A-806A-F0AF6C51B978Q33810001-FA2E7B85-D1A7-4361-A0BB-0B79ADC06236Q33857839-E5D7CB80-2E4B-4A76-BBB9-F02C5AEDDC09Q33905311-1CBA9BA7-FA2E-4DC9-BF71-C8ED4EE9905AQ34218967-5468D362-A8F2-4600-A334-EF8D0A981B23Q34483504-E0FC130A-7197-4501-BCF3-0D7432ABAA83Q35588890-964C4DA7-E062-4555-B9AF-5687C4616E47Q35683731-513CAB14-72A2-4E74-B430-0507285CA2F1Q36286498-1D8F7C7D-AACB-43D1-BE0A-D5593F48BB80Q36329547-07BB31B8-9FBA-4A76-873E-C9E4B86AEC2AQ36739038-86A96A13-3330-48D7-BE5A-A32ADE8A95A9Q37408550-19F3067C-AE1B-4278-B635-C9F8F5BBF3DCQ37564774-257458F5-7187-49FB-B2A2-22CF738F386AQ37589671-7C5009B8-D5F7-4F89-A063-7B1917940398Q37732133-7BE36320-DA69-4DB1-A187-C820368F4779Q37741570-790B0A0E-837E-4A84-A12F-3E7FEE16BB63Q38195120-1D7768E4-9318-468C-9833-164DA7D9FCA4Q38430546-4C84AC44-C938-49F7-8E36-817F61AA2752Q38522618-A75F8EF2-3B2B-425A-ACD1-09C85C559F4FQ38542034-BC08E7CD-9C03-4D3E-A3FD-A8A3D2B3771BQ38577849-A0F8EEFC-A555-47DF-B05D-5897E092E037Q38587627-409C39E1-2648-439F-8E53-C1CCB6E14BF1Q38599353-CBB61109-D317-4E3C-9942-F85F77909022Q38634374-70873126-40BF-46A3-BE95-00E32AF27D38Q38644110-E2BA2FCC-2912-4F2A-97AD-3A93C90DA60FQ38784439-718B580C-7798-4C8F-8928-369E4CFF09C7Q38785314-924D5D56-E9D4-49B9-AB88-9A049D6FDA1EQ38810631-52641B54-168A-4769-BF52-B1DBF8650C1EQ38849985-B2170D6E-E947-4CEF-9A9F-BD4E8B23F6A7
P2860
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
NK cell CD16 surface expressio ...... d metalloprotease-17 (ADAM17).
@ast
NK cell CD16 surface expressio ...... d metalloprotease-17 (ADAM17).
@en
type
label
NK cell CD16 surface expressio ...... d metalloprotease-17 (ADAM17).
@ast
NK cell CD16 surface expressio ...... d metalloprotease-17 (ADAM17).
@en
prefLabel
NK cell CD16 surface expressio ...... d metalloprotease-17 (ADAM17).
@ast
NK cell CD16 surface expressio ...... d metalloprotease-17 (ADAM17).
@en
P2093
P2860
P1433
P1476
NK cell CD16 surface expressio ...... nd metalloprotease-17 (ADAM17)
@en
P2093
Bree Foley
Bruce Walcheck
Dave Ankarlo
Mike Verneris
Rizwan Romee
Sarah Cooley
Todd Lenvik
Xianghua Luo
P2860
P304
P356
10.1182/BLOOD-2012-04-425397
P407
P577
2013-03-13T00:00:00Z